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INTRODUCTION:  Low  grade  ﬁbromyxoid  sarcoma  (LGFMS)1 is a  rare soft  tissue  tumor  involving  deep
soft  tissues  of the  extremities  and  trunk.  Abdominal  location  is  extremely  uncommon  in which  the  few
cases  published  in  the  literature  are  characterized  by  slow  tumoral  progression  and  long  recurrence-free
intervals.
METHODS:  We  report  the  ﬁrst  case  of  an  intra-abdominal  LGFMS  which  was  discovered  incidentally  in  a
42-year-old  woman  presenting  diffuse  peritoneal  nodules  and  hepatic  metastasis  on CT  and  MRI  scans.
RESULTS: The  patient  was  successfully  treated  through  conservative  measures  and remained  asymp-
tomatic  at  the  48  month  follow-up.
CONCLUSIONS:  This  is the ﬁrst reported  case  of LGFMS  with  peritoneal  and  hepatic  metastases.  Despite
the  discovery  of  an advance  disease  at exploration,  the patient  who  refused  a major  surgical  operation
presents  an  uneventful  follow-up  and  long  term  survival.
©  2015  The  Authors.  Published  by  Elsevier  Ltd. on behalf  of Surgical  Associates  Ltd.  This  is an  open
access  article  under  the CC BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Low grade ﬁbromyxoid sarcoma (LGFMS) is a rare entity, ﬁrst
described by Evans in 1987 as a malignant tumor having a decep-
tively benign appearance [1–3]. It is most commonly found in the
trunk and proximal extremities but can occur almost anywhere in
the body [1,2]. There are very few cases of intra-abdominal LGFM
reported in the literature, even fewer with diffuse peritoneal nod-
ules [4–8] and only one case describes a hepatic metastasis in a
patient with LGFMS of the extremities [3].
We  present the ﬁrst case of a 42-year-old woman with an inci-
dental discovery of an intra-abdominal LGFMS with peritoneal and
hepatic metastases. Diagnosis management and the current follow-
up are subsequently discussed.
Abbreviations: LGFMS, low grade ﬁbromyxoid sarcoma; CT, computed tomog-
raphy; MRI, magnetic resonance imaging; PC, peritoneal carcinomatosis; EMA,
epithelial membrane antigen; FISH, ﬂuorescence in situ hybridization; PCI, peri-
toneal carcinomatosis index; HSCTGR, hyalinizing spindle cell tumor with giant
rosettes; RT-PCR, reverse transcription polymerase chain reaction.
∗ Corresponding author at: Surgical Oncology Department, Rue Héger-Bordet, 1,
1000 Brussels, Belgium. Fax: +32 25413141.
E-mail address: gabriel.liberale@bordet.be (G. Liberale).
1 LGFMS low grade ﬁbromyxoid sarcoma.
2. Presentation of case
Following an abdominoplasty in a 42-year-old female patient,
resection of a ﬁbro-adipose tissue protruding through a hernial
defect revealed a LGFMS with positive resection margins.
The patient was  completely asymptomatic and had no relevant
medical or surgical history. The physical examination was  posi-
tive for palpable mobile intra-abdominal masses and nodules in
the Douglas pouch.
An abdominal computed tomography (CT), showed a suspicious
lesion of 49 mm in segment VIII of the liver and multiple dissemi-
nated peritoneal nodules suggesting peritoneal carcinomatosis (PC)
(Fig. 1). An abdominal MRI  showed non-speciﬁc post-operative
fatty stranding in the abdominal wall and conﬁrmed the CT scan
ﬁndings. A whole body 18F-FDG-PET/CT showed only a weak FDG
uptake within some peritoneal nodules (Fig. 2).
A biopsy of the liver lesion was positive for liver metastasis
of a LGFMS. Initially, the diagnosis has been made exclusively on
morphologic criteria including an alternance of collagenized and
myxoid areas (Fig. 3). Negative immunostaining for CD117 and KIT
ruled out a gastro-intestinal stromal tumor. The FISH test analysis
for the FUS gene rearrangement was  non-contributory. Afterwards,
immunostaining with speciﬁc markers including MUC4 and epithe-
lial membrane antigen (EMA) have been performed. EMA  was
negative but MUC4 was strongly and diffusely expressed (Fig. 4).
Serum CA-125 level was normal and serum IgE antibodies for
http://dx.doi.org/10.1016/j.ijscr.2015.06.022
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Coronal contrast abdominal CT shows the hepatic metastatic lesions (white
arrows) and multiple disseminated peritoneal nodules (black arrows).
Entameaba histolytica,  Entameaba granulosus and Schistosoma man-
soni were all negative.
We  opted for an exploratory laparotomy in view of a debulk-
ing surgery and central partial hepatectomy. Peri-operatively, the
peritoneal carcinomatosis index (PCI) was 25/39, indicating a more
advanced peritoneal disease than had been shown on imagery. This
would require a very aggressive surgery including: a large small
bowel resection, a splenectomy, an omentectomy, a low anterior
rectal resection, a partial cystectomy with a partial ureterectomy,
a hysterectomy, a douglasectomy, as well as a partial hepatectomy
and a protective ileostomy. Despite the fact that complete cytore-
ductive surgery could be achieved and that PCI score was  not a
contra-indication for surgery in presence of a low grade disease,
we decided to abort surgery since patient agreed to surgery only
under the condition that we avoid major imposition on her quality
of life. Partial omentectomy was performed for histological exami-
nation. Intra-operative histopathological frozen examination of the
omentum was positive for the LGFMS, conﬁrmed by ﬁnal examina-
tion.
Postoperatively, the patient conﬁrmed her refusal of such an
extensive surgery and also refused any adjuvant palliative treat-
ment proposed after a multi-disciplinary discussion. The patient
undergoes regular clinical and radiological follow-ups at 3 month
intervals. At 48 months of diagnosis, she is still asymptomatic and in
very good general health and the recent abdominal CT scan showed
very discrete progression of the peritoneal carcinomatosis with no
change at the hepatic and thoracic level.
3. Discussion
LGFMS is a rare type of soft-tissue sarcoma described for the
ﬁrst time in 1987 by Evans, characterized by bland histological fea-
tures and, paradoxically, a high mitotic rate [1–3]. During the last 20
years the clinical and histopathological features have been delin-
eated by several series in order to facilitate the diagnosis which was
previously often misinterpreted [9].
Cytogenetically, LGFMS is characterized by a t(7;16)(q33; p11)
or more rarely t(11;16)(p11; p11) translocation, resulting in FUS-
Fig. 2. Coronal Pet/CT image. A: nodules without metabolic activity; B: nodules with
a  weak hypermetabolic activity.
Fig. 3. Histopathological image of LGFMS characterized by ﬁbrous and myxoid areas
and swirling whorled growth patterns with low to moderate cellularity and bland
cells with minimal nuclear pleomorphism.
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Table  1
Studies reporting cases of LGFS.
Age/sex Site of LGFMS Treatment Recurrence/follow up (mo)
Harish et al. [4] 37 years/M Falciform ligament Surgery No/12
Koishi  et al. [5] 38 years/F Omentum Surgery No/36
Park  et al. [6] 43 years/M Colon Surgery No/24
Laurini  et al. [7] 53 years/F Small intestine Surgery No/2
71  years/M Small intestine Surgery No/9
52  years/F Small intestine Surgery Yes/84
69  years/F Small intestine Surgery Unknown
Evans  [3] 33 years/M Omentum, mesentery, and
peritoneum
Surgery (partial excision followed
by 2nd partial excision at 1year)
Yes/60
Chemoradiotherapy adjuvant
Alevizopoulos et al. [8] 48 years/M Renal pelvis Surgery No/7
Fig. 4. MUC4 immunostaining showing strong and diffuse expression.
CREB3L2 or FUS-CREB3L1 fusion genes [10–12]. Recently, MUC4, an
epithelial glycoprotein, has been identiﬁed as a speciﬁc and sensi-
tive marker for LGFMS useful for the differential diagnosis [13]. In
our case, MUC4 was not yet available at the moment of diagnosis.
But, it has been performed afterwards after the publication of Doyle
in 2011 and deﬁnitively conﬁrmed the diagnosis of LGFMS.
The radiological appearance of LGFMS is often insufﬁcient to
establish the diagnosis. Nevertheless, CT and other imagery tools
such as MRI  and ultrasound are able to provide important sup-
plementary information used for differential diagnosis and are
considered as the exams of choice [14].
Although, several studies with insufﬁcient follow-up have sug-
gested a relatively good prognosis of LGFMS, the rate of local
recurrences and late metastasis are proven to be relatively high
[2,3]. In 2011, Evans has demonstrated a high mitotic rate corre-
sponding to 63% of local recurrences and 45% of metastases in a
series with long term follow-up [3]. The metastases developed in
intervals from 0 to 45 years after the primary diagnosis with typical
metastatic sites in the lungs, pleura, chest wall and bone [3].
The golden standard treatment is a complete surgical resec-
tion of any resectable lesion. The rate of local recurrence proved
to be clearly lower in specimens with negative resection margins
[3,12]. Surgical resection is also considered as a treatment of choice
in cases of local recurrence or localized metastasis. Radiotherapy
and chemotherapy could be used for metastatic or non resectable
lesions, however clinical and histological responses seem quite
poor [3].
We  present a case of diffuse intra-abdominal LGFMS with peri-
toneal and hepatic metastases present at the moment of diagnosis.
Although, LGFMS could be seen in more atypical locations like the
retroperitoneum, chest wall or thoracic cavity, the intra-abdominal
location is extremely rare. Only 6 cases had been previously pub-
lished in the literature (Table 1).
Recently, Evans reported a case of diffuse LGFMS of the omen-
tum, mesentery and peritoneum in a 33-year-old-man, treated by
partial excision (omentectomy). At 1 year he underwent another
partial excision, followed by chemoradiotherapy of unknown pro-
tocol. The patient died due to tumor progression at 5 years after
diagnosis [3].
In 2003, Harish et al. published a case of LGFMS of the falciform
ligament in a 37-year-old man  mistaken for a liver haemangioma
on the CT scan. He was  treated by a complete surgical excision and
was recurrence-free at 1 year [4].
In 2003, Yoshiko et al. reported the LGFMS subtype with giant
rosettes cell of omentum in a 38-year-old woman, consulted for
pain and abdominal mass sensations. CT and MRI  revealed a large
multilobular tumor of the right adnexae. The patient underwent
a surgical excision and the histology conﬁrmed the diagnosis of
LGFMS. The patient remains recurrence-free without any adjuvant
treatment at 3 years [5].
A ﬁrst case of LGFMS of the colon was  published by Park
et al. in 2007 in 43-year-old man  who  was  explored surgically
because of an obstructive mass of a hepatic ﬂexure of the colon,
discovered by colonoﬁbroscopic examination without evidence of
cancer by multiple colonoscopic biopsies. The treatment consisted
of right hemicolectomy with right nephrectomy; the patient was
recurrence-free without any other treatment at 2 years [6].
In 2011, four new cases of intestinal LGFMS were reported by
Laurini et al. [7]. The patients, 3 females and 1 male ranging from
52 to 71 years presented a small bowel obstruction and under-
went surgical exploration. One patient was  lost to follow-up, and
two patients were alive without any evidence of disease at 2 and 9
months after surgery. Three patients died of LGFMS at 7 years after
diagnosis. No adjuvant treatment was  delivered.
Finally in 2012, Alevizopoulos et al. reported a LGFMS of the
renal pelvis in a 48-year-old man. The CT scan and ureteroscopy
showed a renal pelvic tumoral mass on the left kidney. The radical
nephro-ureterectomy was  performed and the patient was  free of
local recurrence at the 7 month follow-up [8].
The only reported case of liver metastasis was published by
Evans in 2011 [3]. A 38-year-old woman with LGFMS in the lower
extremities, who had undergone surgical excision with probable
positive margins, presented a local recurrence and lung, sternal,
vertebral and liver metastases at 15 years. One lung and thoracic
spine metastases were resected, respectively; followed by chemo-
radiotherapy. The patient died from a tumor at 18.5 year follow-up.
4. Conclusion
LGFMS is characterized by a high rate of local recurrences and
late metastasis despite a deceptively bland histological appearance.
Our case has shown an indolent course of LGFMS even in the pres-
ence of diffuse intra-abdominal disease and hepatic metastasis,
characteristic for an advanced disease. We  highlight the impor-
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tance to regularly discuss the individual treatment options with
the patients. Since there are no established standardized multi-
modality approaches for the curative treatment, very aggressive
surgery with adjuvant chemotherapy is used. This may  signiﬁcantly
impair the quality of life of patients in whom the disease may
show a very slow, innocuous evolution without any treatment as
reported in the present case. Further studies are needed in order
to establish a more standardized multi-modality approach to this
rare and poorly understood entity.
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